CAJ | 학술논문

目的：探索分析应用尤瑞克林治疗急性进展性脑梗死所产生的临床效果及其安全性。方法选择我院收治的180例急性进展性脑梗死患者作为研究对象并进行分组研究，对照组90例应用常规方式进行治疗，研究组90例在常规治疗的基础上加用尤瑞克林。将两组患者的临床疗效及其安全性进行对比。结果两组研究对象治疗前神经功能缺损症状（NIHSS）评分以及日常生活活动能力（ADL）评分不存在显著性差异（P＞0.05）；研究组治疗后NIHSS评分明显低于对照组，但该组患者的ADL评分则明显高于对照组（P＜0.05）。研究组治疗总有效率为91.11％，明显超过对照组的73.33％（P＜0.05）。两组患者均有5％左右的血压降低、恶心等不良反应发生率，经对症治疗后有效缓解（P＞0.05）。结论针对急性进展性脑梗死患者进行治疗，应用尤瑞克林，能够有效纠正患者神经功能缺损症状，提升其日常活动水平，疗效显著，不良反应少，安全性高，具有极大的推广应用价值。
목적：탐색분석응용우서극림치료급성진전성뇌경사소산생적림상효과급기안전성。방법선택아원수치적180례급성진전성뇌경사환자작위연구대상병진행분조연구，대조조90례응용상규방식진행치료，연구조90례재상규치료적기출상가용우서극림。장량조환자적림상료효급기안전성진행대비。결과량조연구대상치료전신경공능결손증상（NIHSS）평분이급일상생활활동능력（ADL）평분불존재현저성차이（P＞0.05）；연구조치료후NIHSS평분명현저우대조조，단해조환자적ADL평분칙명현고우대조조（P＜0.05）。연구조치료총유효솔위91.11％，명현초과대조조적73.33％（P＜0.05）。량조환자균유5％좌우적혈압강저、악심등불량반응발생솔，경대증치료후유효완해（P＞0.05）。결론침대급성진전성뇌경사환자진행치료，응용우서극림，능구유효규정환자신경공능결손증상，제승기일상활동수평，료효현저，불량반응소，안전성고，구유겁대적추엄응용개치。
ObjectiveTo explore and analyze clinical effects and safety of Urinary Kallidinogenase in treatment of acute progressive cerebral infarction.Methods 180 patients with acute progressive cerebral infarction who were admitted to our hospital were selected as research objects and they were allocated to the control group and the study group, with 90 in each. Patients in the control group were received conventional treatment while patients in the study group were received Urinary Kallidinogenase based on conventional treatment. Clinical effects and safety of two groups were compared. Results The neural function defect symptoms score (NIHSS) and activities of daily living (ADL) scores before treatment of the two groups had no significant differences (P>0.05). The NIHSS scores after treatment of the study group was significantly lower than that of the control group but the ADL score in the study group was significantly higher than that of the control group (P<0.05). Total effective rate of the study group was 91.11% which was significantly higher than that of the control group 73.33% (P<0.05). The incidence rates of adverse reactions including increased blood pressure and nausea of patients in two groups were about 5%. They were relieved after symptomatic treatment (P>0.05).Conclusion Application of Urinary Kallidinogenase in the treatment of patients with acute progressive cerebral infarction can effectively correct the neural function defect symptoms and improve their daily activity level. It has an obvious curative effect, less adverse reactions and high safety which is worthy of promotion and application.